secwatch.observer — SEC 8-K summary
======================================

Issuer:     XOMA Royalty Corp (XOMA)
CIK:        0000791908
Form:       8-K
Filed at:   2026-01-15T23:59:59+00:00
Accession:  0001193125-26-014142
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

XOMA Royalty names Jeffrey Trigilio CFO; Thomas Burns departs after ~19 years
-----------------------------------------------------------------------------

- Thomas Burns stepped down as CFO effective Jan 12, 2026; separation agreement includes $16k/month consulting for 3 months.
- Jeffrey Trigilio appointed CFO effective Jan 12; was CFO/COO at Obsidian Therapeutics and CFO at Cullinan Therapeutics.
- Trigilio receives $515k base salary, 40% target bonus, initial grant of 30,000 performance units, and annual equity grant in 2026.
- Severance for Trigilio: 0.75x base salary, pro-rated bonus, 9-month health benefits; doubled to 1.5x base+bonus on change of control.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/791908/000119312526014142/0001193125-26-014142-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/791908/000119312526014142/d59764d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-014142

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer